Last reviewed · How we verify
endocrinotherapy（doctor's choice）
endocrinotherapy（doctor's choice） is a Small molecule drug developed by Biyun Wang, MD. It is currently in Phase 1 development.
At a glance
| Generic name | endocrinotherapy（doctor's choice） |
|---|---|
| Sponsor | Biyun Wang, MD |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Chidamide in Combination With Abemaciclib and Endocrinotherapy（Doctor's Choice） in Breast Cancer Patients Previously Treated With Palbociclib (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- endocrinotherapy（doctor's choice） CI brief — competitive landscape report
- endocrinotherapy（doctor's choice） updates RSS · CI watch RSS
- Biyun Wang, MD portfolio CI
Frequently asked questions about endocrinotherapy（doctor's choice）
What is endocrinotherapy（doctor's choice）?
endocrinotherapy（doctor's choice） is a Small molecule drug developed by Biyun Wang, MD.
Who makes endocrinotherapy（doctor's choice）?
endocrinotherapy（doctor's choice） is developed by Biyun Wang, MD (see full Biyun Wang, MD pipeline at /company/biyun-wang-md).
What development phase is endocrinotherapy（doctor's choice） in?
endocrinotherapy（doctor's choice） is in Phase 1.